

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

2025 THIRD QUARTERLY REPORT

This announcement is made by 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries collectively, the “**Group**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provision under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company and all members of the board of directors (the “**Board**”) warrant that the contents of the information disclosure are true, accurate and complete without containing any false representations, misleading statements or material omissions.

IMPORTANT NOTICE:

1. The Board, the supervisory committee and the directors, supervisors and senior management of the Company warrant the truthfulness, accuracy, completeness of the 2025 third quarterly report (the “**Quarterly Report**”) of the Company which does not contain any false representations, misleading statements or material omissions, and accept several and joint legal liabilities for its contents.
2. Mr. Zhu Baoguo (朱保國先生), the person-in-charge of the Company, Ms. Si Yanxia (司燕霞女士), the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department), declare that they warrant the truthfulness, accuracy and completeness of the financial information contained in the Quarterly Report.
3. The Quarterly Report was prepared in both Chinese and English. In the event of any discrepancy between the Chinese and the English versions, the Chinese version shall prevail. The financial statements and corresponding information as contained in the Quarterly Report have been prepared in accordance with the China Accounting Standards for Business Enterprises (中國《企業會計準則》). Unless otherwise stated, the currency denominations herein are Renminbi (RMB).
4. Whether the third quarterly report has been audited
☐ Yes ☒ No
5. Items with non-standard opinion from the auditor
☐ Applicable ☒ Not Applicable

I. KEY FINANCIAL DATA

(I) Key Accounting Data and Financial Indicators

Whether the Company has made retrospective adjustments or restatements of accounting data of prior years

☐ Yes ☒ No

	The Reporting Period (July – September 2025)	Period-to-period change	From the beginning of the year to the end of the Reporting Period (January – September 2025)	Period-to-period change
Operating income (RMB)	2,844,001,646.29	1.60%	9,115,914,290.40	0.38%
Net profit attributable to the Shareholders of the Company (RMB)	473,012,359.77	-5.73%	1,754,100,316.30	4.86%
Net profit attributable to the Shareholders of the Company after deducting the extraordinary gains or losses (RMB)	453,566,535.70	-4.58%	1,712,022,009.49	4.98%
Net cash flow from operating activities (RMB)	–	–	2,525,421,252.84	9.42%
Basic earnings per share (RMB/share)	0.52	-3.70%	1.96	8.29%
Diluted earnings per share (RMB/share)	0.52	-3.70%	1.96	8.29%
Weighted average return on net assets	3.41%	Decreased by 0.15 percentage point	12.49%	Increased by 0.86 percentage point

	End of the Reporting Period	End of last year	Change
Total assets (RMB)	24,537,984,410.75	24,455,825,697.18	0.34%
Owners' equity attributable to the shareholders of the Company (RMB)	13,962,841,806.50	13,862,334,189.33	0.73%

Total share capital of the Company as at the trading day prior to disclosure:

Total share capital of the Company as at the trading day prior to disclosure (shares)	904,100,430
---	-------------

Fully diluted earnings per share based on the latest share capital:

Dividends payable to preferred shares (RMB)	–
Interests payable to perpetual bonds (RMB)	–
Fully diluted earnings per share based on the latest share capital (RMB/share)	1.94

(II) Items and Amounts of Extraordinary Gains or Losses

☒ Applicable ☐ Not Applicable

Unit: RMB

Items	Amount for the	Amount from	Explanation
	Reporting Period (July – September 2025)	the beginning of the year to the end of the Reporting Period (January – September 2025)	
Gains or losses on disposal of non-current assets (including the written-off portion of provisions made for asset impairment)	484,433.31	-1,046,879.50	–
Government grants included in profit or loss for the Period (except for government grants closely associated with ordinary operating business of the Company, met national policies and regulations, entitled at fixed level according to certain standards and continuously effected on the Company's profit or loss)	22,164,825.15	81,471,768.38	–
Gains or losses arising from changes in fair value derived from financial assets and financial liabilities held by non-financial enterprises and gains or losses generated on disposal of financial assets and financial liabilities, except for effective hedging activities related to the ordinary operating business of the Company	13,765,757.20	5,541,760.51	–
Other non-operating income and expenditure apart from the above items	-9,624,591.09	-14,382,876.66	–
Less: Effect of income tax	2,278,218.44	12,537,571.93	–
Effect of minority interests (after tax)	5,066,382.06	16,967,893.99	–
Total	19,445,824.07	42,078,306.81	–

Specific Circumstances of Other Profit and Loss Items That Meet the Definition of Non-Recurring Gains and Losses

☐ Applicable ☒ Not Applicable

Explanation on defining items of extraordinary gains or losses as illustrated in the “Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gains or Losses” as items of recurring gains or losses

The Company has not defined any items of extraordinary gains or losses as illustrated in the “Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gains or Losses” as items of recurring gains or losses.

(III) Changes of Key Accounting Data and Financial Indicators and Reasons Thereof

√ Applicable □ Not Applicable

1. Substantial changes of items in the consolidated balance sheet and reasons thereof

Item	Amount at the end of the Period (RMB)	Amount at the beginning of the year (RMB)	Change	Explanation
Financial assets held for trading	1,125,662,829.02	89,363,055.07	1159.65%	Mainly due to the increase in structured deposits in the Period.
Other receivables	52,978,139.31	34,558,694.17	53.30%	Mainly due to the increase in items such as export tax rebates receivable in the Period.
Non-current assets due within one year	215,757,172.72	—	—	Mainly caused by the transfer-in of cash management businesses due within one year.
Other current assets	179,995,483.78	72,684,877.86	147.64%	Mainly due to the addition of new short-term cash management businesses.
Development expenditure	355,884,300.38	220,497,980.76	61.40%	Mainly because the phase III clinical trial of JP1366 tablets was launched, leading to an increase in R&D expenses.
Contract liabilities	69,223,196.19	124,631,997.54	-44.46%	Mainly because part of the prepaid contract payments received in the Period met the revenue recognition criteria and were transferred to revenue.
Non-current liabilities due within one year	106,310,256.66	48,742,085.99	118.11%	Mainly caused by the transfer-in of long-term loans due within one year.
Other current liabilities	3,333,589.53	10,642,182.94	-68.68%	Mainly because part of the prepaid contract payments received in the Period met the revenue recognition criteria and were transferred to revenue, with corresponding transfer of output tax.
Capital reserve	298,831,490.49	529,244,187.41	-43.54%	Mainly because the Company repurchased and cancelled the shares in the Period, offsetting the capital reserve.
Treasury shares	570,313,786.98	196,616,427.46	190.06%	Mainly due to the increase in the Company's share repurchases in the Period.
Other comprehensive income	59,154,405.08	112,180,366.63	-47.27%	Mainly due to fluctuations in exchange rates leading to changes in foreign currency statement translation differences.
Minority interests	1,404,165,248.23	1,043,412,404.71	34.57%	Mainly because the operating profit of non-wholly owned subsidiaries in the Period increased compared with the Previous Period.

2. Substantial changes of items in the consolidated income statement from the beginning of the year to the end of the Reporting Period and reasons thereof

Item	Amount for the Period (RMB) (January – September 2025)	Amount for the Previous Period (RMB) (January – September 2024)	Change	Explanation
Finance expenses	-189,000,313.28	-54,930,249.12	-244.07%	Mainly due to the increase in deposit interest income in the Period.
Investment income	48,706,390.01	25,896,356.13	88.08%	Mainly due to the change in profits and losses of invested associated enterprises.
Gains from changes in fair value	2,447,091.77	-5,500,365.47	144.49%	Mainly due to the market value fluctuation of held securities investment targets.
Credit impairment loss	-7,890,079.59	-326,375.56	-2317.48%	Mainly due to the increase in expected credit losses of receivables.
Asset impairment loss	-17,617,025.91	-60,794,014.54	71.02%	Mainly due to the decrease in inventory write-down provisions.
Non-operating income	2,774,839.97	4,665,883.32	-40.53%	Mainly due to the decrease in gains related to non-ordinary business activities.
Profit and loss attributable to minority interests	376,154,341.33	273,160,909.93	37.70%	Mainly because the operating profit of non-wholly owned subsidiaries in the Period increased compared with the Previous Period.

3. Substantial changes of items in the consolidated cash flow statement from the beginning of the year to the end of the Reporting Period and reasons thereof

Item	Amount for the Period (RMB) (January – September 2025)	Amount for the Previous Period (RMB) (January – September 2024)	Change	Explanation
Subtotal of cash inflow from investing activities	4,935,250,581.28	451,235,389.24	993.72%	Mainly due to the maturity and recovery of structured deposits in the Period.
Subtotal of cash outflow from investing activities	6,561,574,810.45	1,078,556,929.90	508.37%	Mainly due to the addition of new structured deposits in the Period.
Net cash flow from investing activities	-1,626,324,229.17	-627,321,540.66	-159.25%	Mainly due to the addition of new structured deposits in the Period.
Effect of changes in foreign exchange rates on cash and cash equivalents	-56,627,486.05	-21,353,488.46	-165.19%	Mainly due to exchange rate changes, leading to an increase in foreign exchange losses from held foreign currency funds.
Net increase in cash and cash equivalents	-908,282,653.01	-253,011,262.94	-258.99%	Mainly due to the addition of new structured deposits in the Period.

II. USE OF RAISED FUNDS

☐ Applicable ☒ Not Applicable

The Company had no use of raised funds during the Reporting Period.

III. INFORMATION OF SHAREHOLDERS

(I) Total Number of Ordinary Shareholders and Preferred Shareholders with Voting Rights Resumed and Shareholdings of the Top 10 Shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	47,362 (including 47,343 A Shareholders and 19 H Shareholders ^{Note 1)}	Total number of preferred shareholders with voting rights resumed as at the end of the Reporting Period (if any)					–
Shareholdings of the top 10 Shareholders (excluding shares lend through refinancing)							
Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of non-tradable shares held	Pledge, charge or lock-up Share status	Number	
HKSCC Nominees Limited ^{Note 2}	Foreign entity	33.08%	299,053,385	–	–	–	
Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司)	Domestic non-state owned entity	24.49%	221,376,789	–	–	–	
Hong Kong Securities Clearing Company Limited	Foreign entity	2.09%	18,862,640	–	–	–	
Guangzhou Begol Trading Holdings Limited (廣州市保科力貿易公司)	State-owned entity	1.91%	17,306,329	17,306,329	Pledged and locked up	17,306,329	
Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱製藥有限公司)	Domestic non-state owned entity	1.86%	16,830,835	–	–	–	
Guotai Fund Management Co., Ltd. – Social Security Fund 1102 Portfolio (國泰基金管理有限公司 – 社保基金1102組合)	Others	0.65%	5,881,739	–	–	–	
Agricultural Bank of China Limited – CSI 500 Exchange-Traded Open-End Index Securities Investment Fund (中國農業銀行股份有限公司 – 中證500交易型開放式指數證券投資基金)	Others	0.58%	5,285,301	–	–	–	
Peng Xiaoqiang (彭曉強)	Domestic natural person	0.56%	5,080,367	–	–	–	
China Life Insurance Company Limited – Traditional – Ordinary Insurance Products – 005L – CT001 (Shanghai) (中國人壽保險股份有限公司 – 傳統 – 普通保險產品 – 005L – CT001滬)	Others	0.53%	4,793,538	–	–	–	
Industrial and Commercial Bank of China Limited – China-Europe Healthcare Mixed-Style Securities Investment Fund (中國工商銀行股份有限公司 – 中歐醫療健康混合型證券投資基金)	Others	0.40%	3,626,760	–	–	–	

Shareholdings of the top 10 Shareholders without selling restrictions
(excluding shares lend through refinancing, locked shares held by the senior management)

Name of shareholder	Number of publicly traded shares held	Class of shares Class of shares	Number
HKSCC Nominees Limited ^{Note 2}	299,053,385	Overseas listed foreign shares	299,053,385
Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司)	221,376,789	Ordinary shares denominated in RMB	221,376,789
Hong Kong Securities Clearing Company Limited	18,862,640	Ordinary shares denominated in RMB	18,862,640
Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱製藥有限公司)	16,830,835	Ordinary shares denominated in RMB	16,830,835
Guotai Fund Management Co., Ltd. – Social Security Fund 1102 Portfolio (國泰基金管理有限公司－社保基金 1102組合)	5,881,739	Ordinary shares denominated in RMB	5,881,739
Agricultural Bank of China Limited – CSI 500 Exchange-Traded Open-End Index Securities Investment Fund (中國農業銀行股份有限公司－中證500交易型 開放式指數證券投資基金)	5,285,301	Ordinary shares denominated in RMB	5,285,301
Peng Xiaoqiang (彭曉強)	5,080,367	Ordinary shares denominated in RMB	5,080,367
China Life Insurance Company Limited – Traditional – Ordinary Insurance Products – 005L – CT001 (Shanghai) (中國人壽保險股份有限公司－傳統－普通保險產品－ 005L－CT001滬)	4,793,538	Ordinary shares denominated in RMB	4,793,538
Industrial and Commercial Bank of China Limited – China-Europe Healthcare Mixed-Style Securities Investment Fund (中國工商銀行股份有限公司－ 中歐醫療健康混合型證券投資基金)	3,626,760	Ordinary shares denominated in RMB	3,626,760
Shanghai Pudong Development Bank Co., Ltd. – Yinhua CSI Innovative Pharmaceutical Industry Exchange-Traded Open-End Index Securities Investment Fund (上海銀行股份有限公司－銀華中證創新藥產業 交易型開放式指數證券投資基金)	3,534,167	Ordinary shares denominated in RMB	3,534,167

Description of connection or acting-in-concert relationship of the above shareholders	(1) On 2 January 2004, Joicare Pharmaceutical Group Industry Co., Ltd. (“Joicare”) and Guangzhou Begol Pharmaceutical and Health Products Import & Export Co., Ltd.* (廣州保科力醫藥保健品進出口有限公司) (formerly known as Guangzhou Begol Trading Holdings Limited* (廣州市保科力貿易公司)) (“Begol”) entered into a Share Transfer and Custody Agreement and a Share Pledge Agreement, pursuant to which the 6,059,428 shares of the Company held by Begol as original domestic legal shares (the number of shares was increased to 7,877,256 shares after the Company’s implementation of 2014 Equity Distribution, the number of shares was increased to 10,240,432 shares after the Company’s implementation of 2016 Equity Distribution, the number of shares was increased to 13,312,561 shares after the Company’s implementation of 2017 Equity Distribution and the number of shares was increased to 17,306,329 shares after the Company’s implementation of 2018 Equity Distribution) were directly transferred, entrusted and pledged to Joicare; (2) Shenzhen Haibin Pharmaceutical Co., Ltd. was a controlling subsidiary directly and indirectly owned by Joicare as to 100% equity interest; (3) the Company was not aware of whether the other shareholders mentioned above are related parties or persons acting-in-concert as defined in the Administrative Measures for the Takeover of Listed Companies (《上市公司收購管理辦法》).
---	--

Description of the top 10 shareholders involved in margin financing and securities lending business (if any)	Among the above-mentioned shareholders, Peng Xiaoqiang holds 5,068,600 shares through a margin securities account.
--	--

- Notes:*
1. The shareholdings of the above top 10 shareholders are listed in accordance with the data in the register of members as at 30 September 2025 provided by Shenzhen Branch of China Securities Depository and Clearing Corporation Limited and Tricor Investor Services Limited in Hong Kong.
 2. HKSCC Nominees Limited is a nominee holder of H Shares of the Company, and the Company cannot ascertain whether such H Shares are subject to any pledge or lock-up, and such H Shares held in the name of HKSCC Nominees Limited included 163,364,672 H Shares of the Company held by Topsino Industries Limited (天誠實業有限公司), which is a wholly-owned subsidiary of Joicare, the controlling shareholder of the Company.
 3. There is the special repurchase security account among the top 10 shareholders of the Company, and the number of shares held is 15,376,845 shares, which have not been cancelled.

Shareholders holding more than 5%, top 10 Shareholders, and top 10 Shareholders of circulation shares without selling restrictions participating in refinancing business shares lend

☐ Applicable ☒ Not Applicable

Changes compared to the Previous Period due to lending/returning for refinancing by the top 10 Shareholders and the top 10 Shareholders of circulation shares without selling restrictions

☐ Applicable ☒ Not Applicable

(II) Total Number of Preferred Shareholders of the Company and Shareholdings of the Top 10 Preferred Shareholders

☐ Applicable ☒ Not Applicable

IV. OTHER IMPORTANT EVENTS

☒ Applicable ☐ Not Applicable

The Progress of Repurchase of Shares

1. The progress of repurchase of A Shares

As at 30 September 2025, the Company made a total repurchase of 15,376,845 A Shares of the Company by means of centralized bidding transactions, accounting for 1.70% of the total share capital of the Company. The highest purchase price was RMB41.99 per share, while the lowest purchase price was RMB33.21 per share. The aggregate amount of funds used for the repurchase was RMB570,228,471.25 (excluding the transaction costs). The above mentioned repurchase complied with the Company's existing Share Repurchase Scheme.

2. The progress of repurchase of H Shares

As at 30 September 2025, the Company has not repurchased any H-shares.

V. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statements

Consolidated Balance Sheet

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount at the End of the Period	Amount at the Beginning of the Year
Current assets:		
Monetary funds	9,918,953,931.89	10,827,146,984.92
Financial assets held for trading	1,125,662,829.02	89,363,055.07
Bills receivable	1,006,862,636.69	1,313,604,720.17
Accounts receivables	2,271,026,928.60	1,935,502,036.72
Receivables financing		
Prepayments	144,257,350.88	149,477,979.10
Other receivables	52,978,139.31	34,558,694.17
Of which: Interest receivable		
Dividends receivable		
Inventories	1,656,634,262.03	1,997,642,296.29
Contract assets		
Held-for-sale assets		
Non-current assets due within one year	215,757,172.72	
Other current assets	179,995,483.78	72,684,877.86
Total current assets	16,572,128,734.92	16,419,980,644.30
Non-current assets:		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments	1,085,081,709.92	1,056,220,316.06
Other equity instrument investments	560,246,965.62	561,645,609.43
Other non-current financial assets		
Investment properties	9,295,191.56	9,925,854.14
Fixed assets	4,050,259,754.75	4,254,805,388.16
Construction in progress	282,697,347.75	257,366,336.12
Productive biological assets		
Oil and gas assets		
Right-of-use assets	25,205,455.46	25,083,211.98
Intangible assets	478,720,971.44	403,681,866.63
Development expenditure	355,884,300.38	220,497,980.76
Goodwill	124,911,302.94	124,911,302.94
Long-term deferred expenses	161,037,290.44	175,748,366.88
Deferred income tax assets	416,195,376.50	356,345,428.36
Other non-current assets	416,320,009.07	589,613,391.42
Total non-current assets	7,965,855,675.83	8,035,845,052.88
Total assets	24,537,984,410.75	24,455,825,697.18

Item	Amount at the End of the Period	Amount at the Beginning of the Year
Current liabilities:		
Short-term loans	2,440,000,000.00	2,455,000,000.00
Financial liabilities held for trading	6,954,006.35	8,096,946.08
Bills payables	740,350,163.48	965,581,088.61
Accounts payables	563,505,441.54	618,397,523.74
Receipts in advance		
Contract liabilities	69,223,196.19	124,631,997.54
Employee benefits payables	301,129,714.47	330,257,959.08
Taxes and surcharge payables	261,225,725.44	202,697,245.73
Other payables	2,866,238,751.72	2,861,381,342.08
Of which: Interest payable		
Dividends payable	9,073,481.38	9,890,041.38
Held-for-sale liabilities		
Non-current liabilities due within one year	106,310,256.66	48,742,085.99
Other current liabilities	3,333,589.53	10,642,182.94
Total current liabilities	7,358,270,845.38	7,625,428,371.79
Non-current liabilities:		
Long-term loans	1,357,061,774.57	1,465,735,112.37
Bonds payables		
Leasing liabilities	13,978,198.72	13,102,527.71
Long-term payables		
Long-term employee benefits payables		
Provisions		
Deferred gains	231,180,588.88	238,422,836.35
Deferred income tax liabilities	210,485,948.47	207,390,254.92
Other non-current liabilities		
Total non-current liabilities	1,812,706,510.64	1,924,650,731.35
Total liabilities	9,170,977,356.02	9,550,079,103.14
Share capital	904,100,430.00	911,345,730.00
Other equity instruments		
Of which: Preferred shares		
Perpetual bonds		
Capital reserve	298,831,490.49	529,244,187.41
Less: treasury shares	570,313,786.98	196,616,427.46
Other comprehensive income	59,154,405.08	112,180,366.63
Special reserve		
Surplus reserve	744,801,154.15	744,801,154.15
Undistributed profits	12,526,268,113.76	11,761,379,178.60
Total equity attributable to shareholders of the parent company	13,962,841,806.50	13,862,334,189.33
Minority interests	1,404,165,248.23	1,043,412,404.71
Total shareholders' (or owners') equity	15,367,007,054.73	14,905,746,594.04
Total liabilities and shareholders' (or owners') equity	24,537,984,410.75	24,455,825,697.18

Chairman of the Board and Legal Representative:
Zhu Baoguo

Executive Director and President:
Tang Yanggang

Chief Financial Officer:
Si Yanxia

Head of Accounting Department:
Si Yanxia

Consolidated Income Statement from the Beginning of the Year to the End of the Reporting Period

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount for the Period (January – September 2025)	Amount for the Previous Period (January – September 2024)
I. Operating income	9,115,914,290.40	9,081,603,788.36
Less: Operating costs	3,064,284,474.55	3,104,994,916.67
Tax and surcharge	113,801,771.98	104,952,254.81
Selling expenses	2,603,992,435.13	2,456,192,166.74
Administrative expenses	449,643,456.11	472,580,469.22
R&D expenses	683,264,467.54	734,493,897.75
Finance expenses	-189,000,313.28	-54,930,249.12
Of which: Interest expenses	43,698,120.84	68,262,462.24
Interest income	242,202,781.32	146,128,180.20
Add: Other income	95,669,068.02	93,195,566.84
Investment income (“-” represents losses)	48,706,390.01	25,896,356.13
Of which: Income from investments in associates and joint ventures	45,883,152.74	18,288,587.10
Gains on derecognition of financial assets at amortized cost (“-” represents losses)		
Gains from hedging net exposure (“-” represents losses)		
Gains from changes in fair value (“-” represents losses)	2,447,091.77	-5,500,365.47
Credit impairment loss (“-” represents losses)	-7,890,079.59	-326,375.56
Asset impairment loss (“-” represents losses)	-17,617,025.91	-60,794,014.54
Gains from disposal of assets (“-” represents losses)	-315,529.31	-370,399.04
II. Operating profit (“-” represents losses)	2,510,927,913.36	2,315,421,100.65
Add: Non-operating income	2,774,839.97	4,665,883.32
Less: Non-operating expenditure	17,157,716.63	17,228,592.52
III. Total profit (“-” represents total losses)	2,496,545,036.70	2,302,858,391.45
Less: Income tax expenses	366,290,379.07	356,963,491.89
IV. Net profit (“-” represents net losses)	2,130,254,657.63	1,945,894,899.56
(I) Classified by continuing operations:		
Of which: Net profit from continuing operations (“-” represents net losses)	2,130,254,657.63	1,945,894,899.56
Net profit from discontinued operations (“-” represents net losses)		
(II) Classified by attribution to ownership:		
Of which: Net profit attributable to shareholders of the parent company (“-” represents net losses)	1,754,100,316.30	1,672,733,989.63
Profit and loss attributable to minority interests (“-” represents net losses)	376,154,341.33	273,160,909.93

Item	Amount for the Period (January – September 2025)	Amount for the Previous Period (January – September 2024)
V. Other comprehensive net income after taxation	-59,022,809.11	-49,894,257.61
Other comprehensive net income after taxation attributable to shareholders of the parent company	-60,177,610.18	-49,606,276.66
(I) Other comprehensive income not to be reclassified into profit or loss	-2,817,351.10	-58,575,448.32
1. Changes in remeasurement of defined benefit plans		
2. Other comprehensive income not to be reclassified into profit or loss under equity method		
3. Changes in fair value of other equity instrument investments	-2,817,351.10	-58,575,448.32
4. Changes in fair value of enterprise's own credit risk		
5. Others		
(II) Other comprehensive income to be reclassified into profit or loss	-57,360,259.08	8,969,171.66
1. Other comprehensive income to be reclassified into profit or loss under equity method	4,899.65	-383,527.54
2. Changes in fair value of other debt investments		
3. Financial assets reclassified into other comprehensive income		
4. Credit impairment provision for other debt investments		
5. Reserve for cash flow hedging (effective portion of profit or loss from cash flow hedging)		
6. Translation differences of financial statements denominated in foreign currency	-57,365,158.73	9,352,699.20
7. Others		
Other comprehensive net income after taxation attributable to minority interests	1,154,801.07	-287,980.95
VI. Total comprehensive income	2,071,231,848.52	1,896,000,641.95
Total comprehensive income attributable to shareholders of the parent company	1,693,922,706.12	1,623,127,712.97
Total comprehensive income attributable to minority interests	377,309,142.40	272,872,928.98
VII. Earnings per share		
(I) Basic earnings per share	1.96	1.81
(II) Diluted earnings per share	1.96	1.81

Chairman of the Board and Legal Representative: <i>Zhu Baoguo</i>	Executive Director and President: <i>Tang Yanggang</i>	Chief Financial Officer: <i>Si Yanxia</i>	Head of Accounting Department: <i>Si Yanxia</i>
---	--	---	---

Consolidated Cash Flow Statement from the Beginning of the Year to the End of the Reporting Period

Prepared by: Livzon Pharmaceutical Group Inc.

Unit: RMB

Item	Amount for the Period (January – September 2025)	Amount for the Previous Period (January – September 2024)
I. Cash flow from operating activities:		
Cash received from sale of goods and services rendered	9,744,458,934.54	9,877,413,424.19
Refund of taxes and levies	67,343,277.76	61,319,520.23
Cash received relating to other operating activities	343,644,802.31	278,375,294.28
Subtotal of cash inflow from operating activities	10,155,447,014.61	10,217,108,238.70
Cash paid for purchase of goods and services received	2,340,361,803.79	2,548,981,042.82
Cash paid to and on behalf of employees	1,352,705,534.48	1,296,813,399.77
Payments for various taxes and levies	1,067,714,253.16	1,133,102,962.42
Cash paid relating to other operating activities	2,869,244,170.34	2,930,295,471.41
Subtotal of cash outflow from operating activities	7,630,025,761.77	7,909,192,876.42
Net cash flow from operating activities	2,525,421,252.84	2,307,915,362.28
II. Cash flow from investing activities:		
Cash received from disposal of investments	4,905,983,830.21	437,976,402.50
Cash received on investment income	27,860,344.04	12,838,374.07
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	1,281,158.00	420,612.67
Net cash received from disposal of subsidiaries and other operating units		
Cash received relating to other investing activities	125,249.03	
Subtotal of cash inflow from investing activities	4,935,250,581.28	451,235,389.24
Cash payments for acquisition of fixed assets, intangible assets and other long-term assets	495,411,345.73	405,237,689.81
Cash payments for investments	6,061,646,109.43	671,914,636.75
Net cash paid for acquisition of subsidiaries and other operating units		
Cash paid relating to other investing activities	4,517,355.29	1,404,603.34
Subtotal of cash outflow from investing activities	6,561,574,810.45	1,078,556,929.90
Net cash flow from investing activities	-1,626,324,229.17	-627,321,540.66

Item	Amount for the Period (January – September 2025)	Amount for the Previous Period (January – September 2024)
III.Cash flow from financing activities:		
Cash received from investments	28,799,064.00	161,751,999.95
Of which: Cash received by subsidiaries from investments of minority interests	28,799,064.00	
Cash received from borrowings	2,870,140,000.00	3,004,143,152.42
Cash received relating to other financing activities		1,062,615.02
Subtotal of cash inflow from financing activities	2,898,939,064.00	3,166,957,767.39
Cash paid on repayment of debts	2,935,993,209.00	3,044,697,628.28
Cash paid for distribution of dividends, profits or interest	1,126,904,288.33	1,640,266,373.96
Of which: Dividends and profits paid to minority interests by subsidiaries	105,966,560.00	319,631,193.75
Cash paid relating to other financing activities	586,793,757.30	394,245,361.25
Subtotal of cash outflow from financing activities	4,649,691,254.63	5,079,209,363.49
Net cash flow from financing activities	-1,750,752,190.63	-1,912,251,596.10
IV.Effect of changes in foreign exchange rates on cash and cash equivalents	-56,627,486.05	-21,353,488.46
V. Net increase in cash and cash equivalents	-908,282,653.01	-253,011,262.94
Add: Balance of cash and cash equivalents at the beginning of the Period	10,817,816,661.30	10,976,366,402.44
VI.Balance of cash and cash equivalents at the end of the Period of the Period	9,909,534,008.29	10,723,355,139.50

<i>Chairman of the Board and Legal Representative:</i>	<i>Executive Director and President:</i>	<i>Chief Financial Officer:</i>	<i>Head of Accounting Department:</i>
<i>Zhu Baoguo</i>	<i>Tang Yanggang</i>	<i>Si Yanxia</i>	<i>Si Yanxia</i>

(II) Adjustments to the Financial Statements as at the Beginning of the Year Due to the Application of New Accounting Standards for the First Time Since 2025

☐ Applicable ☒ Not Applicable

(III) Audit Report

Whether the third quarterly report has been audited

☐ Yes ☒ No

The third quarterly report of the Company has not been audited.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
23 October 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

* For identification purpose only